Medicine Park Co., Ltd.
Biotech company developing therapeutics for connective tissue disorders using low‑molecular‑weight biopolymer technology. Focus areas include intra‑articular injectable treatments for osteoarthritis and other joint disorders, veterinary injectable therapeutics, and development of functional ingredient materials. The company operates R&D programs, pursues IND preparation and preclinical studies, and collaborates with universities, research institutes and industry partners.
Industries
N/A
Nr. of Employees
small (1-50)
Medicine Park Co., Ltd.
02455 서울특별시 동대문구 회기로 117-3, 지상 3층 304호 (회기동, 서울바이오허브 연구실험동)
Patents
Compositions for treating joint or connective tissue disease comprising dextran or poloxamer
US-12576105-B2
View DetailsCompositions for treating joint or connective tissue disease comprising dextran or poloxamer
US-11801260-B2
View DetailsCompositions for treating joint or connective tissue disease comprising dextran or poloxamer
US-11278565-B2
View Details
Compositions for treating joint or connective tissue disease comprising dextran or poloxamer
US-12576105-B2
View DetailsCompositions for treating joint or connective tissue disease comprising dextran or poloxamer
US-11801260-B2
View DetailsCompositions for treating joint or connective tissue disease comprising dextran or poloxamer
US-11278565-B2
View DetailsProducts
Human intra‑articular injectable for knee osteoarthritis
Therapeutic intra‑articular injectable candidate intended to treat knee osteoarthritis; progression includes preclinical development and IND preparation.
Veterinary intra‑articular injectable therapeutics
Injectable products developed for veterinary use (e.g., companion animals and racehorses).
Injectable therapies for shoulder disorders
Intra‑articular or peri‑articular injectable candidates for shoulder conditions such as adhesive capsulitis and rotator cuff injuries.
Health‑functional ingredient materials
Development of individual‑recognition health‑functional raw materials aimed at muscle, cognitive, joint/cartilage and bone health claims.
Human intra‑articular injectable for knee osteoarthritis
Therapeutic intra‑articular injectable candidate intended to treat knee osteoarthritis; progression includes preclinical development and IND preparation.
Veterinary intra‑articular injectable therapeutics
Injectable products developed for veterinary use (e.g., companion animals and racehorses).
Injectable therapies for shoulder disorders
Intra‑articular or peri‑articular injectable candidates for shoulder conditions such as adhesive capsulitis and rotator cuff injuries.
Health‑functional ingredient materials
Development of individual‑recognition health‑functional raw materials aimed at muscle, cognitive, joint/cartilage and bone health claims.
Services
Collaborative research arrangements with universities, research institutes, industry partners and government agencies to advance biomaterial and therapeutic programs.
Collaborative research arrangements with universities, research institutes, industry partners and government agencies to advance biomaterial and therapeutic programs.
Expertise Areas
- Connective tissue disorder therapeutics
- Biomaterials (low‑molecular‑weight biopolymers)
- Intra‑articular injectable therapies
- Preclinical development and IND preparation
Key Technologies
- Low‑molecular‑weight biopolymers
- Injectable formulation technologies
- Preclinical animal model studies
- Assays for anti‑inflammatory cytokine modulation
News & Updates
Selected for a program providing global advisor network, 1:1 consulting and IR pitching support for overseas expansion and fundraising.
Presented technology for treatment and prevention of connective tissue disorders using low‑molecular‑weight biopolymer materials at a women‑focused demo day.
Exhibited technology and participated in partnering and poster sessions at Korea Life Science Week 2021.
Interview feature introducing the company's programs for degenerative connective tissue disorder therapeutics and health‑functional raw materials.
Recognition as a corporate R&D institute (기업부설연구소 인정서).
Official venture company confirmation (벤처기업 확인서).
Selected for a program providing global advisor network, 1:1 consulting and IR pitching support for overseas expansion and fundraising.
Presented technology for treatment and prevention of connective tissue disorders using low‑molecular‑weight biopolymer materials at a women‑focused demo day.
Exhibited technology and participated in partnering and poster sessions at Korea Life Science Week 2021.
Interview feature introducing the company's programs for degenerative connective tissue disorder therapeutics and health‑functional raw materials.
Recognition as a corporate R&D institute (기업부설연구소 인정서).
Official venture company confirmation (벤처기업 확인서).